Cadrenal Therapeutics Q2 2023 update; cash $9.6M, tecarfarin expansion into LVADs

Cadrenal Therapeutics, Inc.

Q2 2023 operating expenses (excl. non-cash) totaled $835,000; cash balance $9.6M as of Aug 14.
Completed $7.5M private placement at $1.75 per share with an institutional investor.
Expanded tecarfarin development to LVAD patients; estimated $600M annual U.S. addressable market.
Appointed cardiovascular executive Robert Lisicki to the board of directors.
Combined addressable market for ESKD/AFib and LVADs estimated at $1.6B annually in U.S.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Cadrenal Therapeutics, Inc. reported financial results for the quarter ended June 30, 2023.

Period: the quarter ended June 30, 2023
Result: reported results

Exact text from the filing

issued a press release that included financial information for the fiscal quarter ended June 30, 2023.

View on SEC.gov

Browse all earnings releases →

Cadrenal Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001213900-23-065305

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.